Summary Antibody targeted therapy of cancer results in anti-antibody production which prevents repeated treatment. Cyclosporin A (CsA) has been used to suppress this response in patients treated with a radiolabelled antibody to carcinoembryonic antigen (CEA). Patients with CEA producing tumours received a minimum of two courses consisting of an injection of radiolabelled antibody and CsA, 24 mg kg-1 day-1, for 6 days; each course was given at 2 week intervals. Two weeks after the completion of the second course the mean human antimouse antibody (HAMA) levels were 3.5 ug ml -1 (s.d. 2.7) in 3 patients receiving CsA and 1,998 pg ml-1 (s.d. 387) in 3 patients not receiving the drug. Clearance of antitumour antibody was accelerated and tumour localisation absent when HAMA levels exceeded 30 pgml-1. With lower levels of HAMA in the CsA-treated patients, further antitumour antibody accumulated in the tumour after each dose. Further therapy with antitumour antibody and CsA lead to the development of HAMA, but this was less than 25% of the amount in patients not given CsA. In this preliminary study up to 4 times as many doses of antitumour antibody could be usefully given when CsA was used. This increases the potential for effective antibody targeted therapy of cancer.
Therapy of cancer with intravenous antitumour mouse monoclonal antibodies alone or conjugated to radionuclides or toxins has produced tumour responses but these are seldom sustained (Meeker et al., 1985 , Lenhard et al., 1985 , Spitler et al., 1987 . Repeated therapy would probably be more effective but is prevented by the formation of human antimouse antibody (HAMA) after one or more injections of antitumour antibody (Meeker et al., 1985 , Carrasquillo et al., 1984 , Shawler et al., 1985 . This causes hypersensitivity reactions and prevents antitumour antibody from localising in the tumour.
CsA is a powerful inhibitor of humoral immunity (Borel et al., 1976) and has recently been shown in the accompanying paper to prevent the antibody response to repeated injections of mouse monoclonal antibodies in rabbits (Ledermann et al., 1988) . The suppression of the anti-antibody response is likely to benefit those patients treated with repeated injections of antibody targeted therapy when the cytotoxic action of the conjugate does not depend on host natural effector mechanisms which may be perturbed by the complex actions of CsA on the immune system. This study investigates the effect of CsA on the formation of HAMA in patients with CEA-producing tumours treated with repeated doses of a 131 -iodine (131 I)-labelled mouse monoclonal antibody to CEA.
Patients and methods

Patients
Six patients with CEA-producing tumours and performance status 0-2 (WHO Handbook, 1979) were investigated. All had locally recurrent or metastatic tumour and conventional therapy had failed. HAMA levels were below 5 Mg ml -.
Details of individual patients are given in Table I .
Methods
Mouse monoclonal IgG1 antibody to CEA (A5B7) (Harwood et al., 1986) was produced in supernatant culture and protein A purified. Before radiolabelling with 1311 by the chloramine T method, A5B7 was centrifuged at 48,000g for 2h as previously described (Ledermann et al., 1988) .
After negative intradermal testing with 10,pg antibody, the HAMA levels were measured by enzyme immunoassay. Dilutions of serum in PBS containing 0.05% Tween and 0.1% bovine serum albumin were incubated for 2h at room temperature in microtitre wells coated with 10 pgml-l A5B7 in carbonate-bicarbonate buffer, pH 9.6. After washing, wells were incubated with goat anti-human IgG conjugated to alkaline phosphatase (Sigma) followed by the addition of pnitrophenyl phosphate. The absorbance was recorded on a Titertek Multiskan. The assay was standardised using HAMA immunopurified on an A5B7-Sepharose-CL4B column.
Anti-idiotypic antibody was measured by inhibition of binding of HAMA to A5B7, as above, after serum, containing 150 ng ml -1 of human IgG anti-mouse antibody was incubated at room temperature overnight with 1,000 pgml-1 of either A5B7 or SB1O. The latter is a mouse monoclonal antibody of the same isotype directed against human chorionic gonadotrophin and does not react with CEA.
Toxicity and response were characterised using WHO criteria (WHO Handbook, 1979) .
Results
HAMA formation
Three patients received 1311-A5B7 with CsA and three without. Details of the patients are shown in Table I . Two Br. J. Cancer (1988), 58, 654-657 Anti-idiotypic antibody could be detected in all patients at some time during therapy. It accounted for a median of 32.5% of the HAMA response and the quantity tended to increase with successive therapy (Figure 2) . No difference in the pattern of the IgG response to the constant and variable region of the A5B7 molecule was seen in the patients who received CsA and those given radiolabelled antitumour antibody alone. When HAMA production was suppressed by CsA so too was antiidiotype.
Clearance of 131I-ASB7 and tumour localisation Patients with HAMA below 6 pg ml -1 at the start of a course of treatment showed a similar rate of clearance of 131I-A5B7 with each course (Figure 3a) . One patient had an increase in HAMA to 39 pg ml-1 before the second dose and showed more rapid clearance (Figure 3b ). Serial gamma camera images showed that when HAMA levels were below 6pgml-1, repeated therapy led to further accumulation of radioactivity in the tumour with each dose. There was no difference in the general distribution (Figure 4) . The patient in Figure 3b whose HAMA levels rose to 39 pg ml-1 before the second dose of 131I-A5B7 showed no tumour localisation although this had been good with the first dose when the HAMA level was 1 gml-1. This was associated with rapid clearance of 1311-A5B7 in the presence of HAMA ( Figure 5 ). There was pain relief and a fall in serum CEA levels after the first dose but none after the second.
Toxicity
The patient who had a second injection of 131I-A5B7 in the presence of HAMA values of 39 pg ml1 developed an allergic reaction 6min after the start of antibody infusion with flushing, faintness, epigastric pain and vomiting. It resolved rapidly after injection of chlorpheniramine and hydrocortisone. One patient had a rigor lasting 30 minutes after antibody administration. Patients receiving CsA had nausea and anorexia lasting for the duration of CsA administration (2 WHO grade I and 1 grade III). Two had headaches and 1 had grade I renal impairment. Myelosuppression, attributed to radiation by 1311 occurred in patients previously given chemotherapy or radiotherapy regardless of whether CsA was administered. Two patients had grade IV and 2 grade II thrombocytopaenia; one had leucopaenia of grade II and 1 of grade IV. One patient had anaemia, grade I. Nadirs were from 4 to 15 weeks after the first therapy. -Te-vT- 
Discussion
Immunogenicity is a potential problem in the therapeutic use of macromolecular products of biotechnology which can prevent their repeated administration. This paper shows that CsA permits repeated therapy with antitumour monoclonal antibodies by suppressing HAMA formation in patients. More antibody accumulates in the tumour with each dose and up to 4 times as many doses could usefully be given with CsA as without.
Recently it has been shown that the response of rabbits to 2 doses of mouse monoclonal antibodies could be completely suppressed by CsA (Ledermann et al., 1988) . Borel et al. (1977) demonstrated that optimal immunosuppression was achieved by maximum doses of CsA at the time of immunisation. The dose of CsA given was the maximum amount that has previously been tolerated in patients. However, an eventual escape from immunosuppression occurred in spite of starting CsA 2 days before the antibody administration to ensure high concentrations of CsA at the time of antigen challenge.
It is possible that the small quantities of 1311-A5B7 remaining after the completion of CsA therapy led to late immunisation. At this time the blood concentration of antibody, projected from the clearance curve, was 15 ngml-'. Alternatively, the immune system may have been primed before exposure to 1311-A5B7. Whilst this can occur following diagnostic doses of radiolabelled antibody for tumour localisation (Pimm et al., 1983) , most patients who have pre-existing HAMA have no history of exposure to mouse immunoglobulins (Shawler et al., 1985; Schroff et al., 1985) . These pre-existing HAMA, at least of the IgM class, have been shown to be rheumatoid factors that cross react with murine IgG (Courtenay-Luck et al., 1987) . Future studies will investigate whether continuous therapy at lower doses of CSA will give more prolonged suppression of HAMA production.
One additional patient studied had raised HAMA levels 10 30 50 Hours before therapy and CsA failed to prevent an increase in HAMA levels before the second dose of antibody. This is in keeping with the expected failure of CsA to suppress the secondary immune response (Lindsey et al., 1982) . Although it has been suggested that HAMA formation may result from intradermal testing with antibody it could not account for the differences in HAMA levels seen in this study since all patients had the same intradermal testing.
CsA did not prevent the anti-idiotypic response from occurring in the patients who eventually escaped immunosuppression. An anti-idiotypic antibody was seen as a component of pre-existing anti-mouse antibody in two patients; one who had less than 5/,tgml-1 HAMA and the other with raised pre-existing antibody (data not shown). It is therefore unlikely that the combination of CsA and Fab fragments, which are less immunogenic than intact antibody (Carrasquillo et al., 1984) will prevent the anti-idiotypic response. Hybrid antibodies containing a mouse variable region and human constant region may be less immunogenic but the potential for an anti-idiotypic response would still appear to exist.
The anti T cell antibody, OKT3 has not succeeded in preventing HAMA formation (Jaffers et al., 1986) . Immunosuppression with large doses of cyclophosphamide has reduced the incidence of HAMA (Thistlewaite et al., 1986) . However, this is likely to lead to haematological toxicity which might compromise repeated therapy with immunoconjugates. Further reasons why CsA appears preferable to other means of suppressing HAMA and the case for ultracentrifugation of antibody are discussed in the accompanying paper (Ledermann et al., 1988) .
Concern that immunosuppression with CsA might accelerate tumour growth was not supported by the preliminary data here. Although tumour responses were not seen by WHO criteria, patients were necessarily at a late stage of disease with large tumours and antibody localisation is likely to be more efficient when tumours are small (Pedley et al., 1987) . Tumour responses in other studies , Lenhard et al., 1985 , Spitler et al., 1987 , Pectasides et al., 1986 could probably be augmented if therapy could be repeated. Also, dual phase systems promise to have a much higher therapeutic ratio than has been attained to date. In these the therapeutic agent is given after the antitumour antibody and localises to antibody already on the tumour (Raso et al., 1982) or is activated at the tumour site by an enzyme linked to antibody (Bagshawe, 1987) . The ability to give repeated therapy provided by CsA is likely to improve the results of these approaches to cancer therapy.
